Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-5.55 Insider Own0.00% Shs Outstand58.61M Perf Week-3.87%
Market Cap10.40M Forward P/E- EPS next Y-22.08 Insider Trans- Shs Float17.45M Perf Month-48.17%
Income-98.59M PEG- EPS next Q-7.89 Inst Own4.27% Short Float10.26% Perf Quarter-87.58%
Sales10.25M P/S1.01 EPS this Y-17.05% Inst Trans216.69% Short Ratio1.46 Perf Half Y-93.98%
Book/sh1.47 P/B0.41 EPS next Y31.46% ROA-62.71% Short Interest1.79M Perf Year-98.95%
Cash/sh0.40 P/C1.48 EPS next 5Y- ROE-72.08% 52W Range0.58 - 58.88 Perf YTD-95.38%
Dividend Est.- P/FCF- EPS past 5Y79.31% ROI-85.83% 52W High-98.99% Beta2.12
Dividend TTM- Quick Ratio0.87 Sales past 5Y0.00% Gross Margin-7.12% 52W Low2.76% ATR (14)0.19
Dividend Ex-Date- Current Ratio1.47 EPS Y/Y TTM70.31% Oper. Margin-1032.48% RSI (14)20.57 Volatility5.35% 11.44%
Employees103 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin-961.87% Recom1.00 Target Price94.93
Option/ShortNo / No LT Debt/Eq0.06 EPS Q/Q94.33% Payout- Rel Volume1.49 Prev Close0.61
Sales Surprise-35.53% EPS Surprise34.55% Sales Q/Q- EarningsMay 13 AMC Avg Volume1.23M Price0.60
SMA20-31.73% SMA50-81.63% SMA200-94.05% Trades Volume1,831,603 Change-2.42%
Date Action Analyst Rating Change Price Target Change
Apr-18-22Initiated Noble Capital Markets Outperform
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Today 08:00AM
Jul-10-24 04:30PM
Jul-09-24 09:15AM
Jul-08-24 05:00PM
08:00AM Loading…
Jul-01-24 11:07AM
Jun-28-24 04:05PM
Jun-27-24 11:01AM
Jun-26-24 04:40PM
03:13PM Loading…
Jun-25-24 08:00AM
Jun-21-24 07:30AM
Jun-20-24 08:00AM
Jun-18-24 12:31PM
Jun-17-24 08:00AM
Jun-13-24 05:00PM
Jun-12-24 10:06AM
Jun-11-24 05:17PM
Jun-10-24 12:14PM
11:55AM Loading…
Jun-06-24 11:00AM
Jun-05-24 08:00AM
Jun-03-24 08:00AM
May-30-24 08:00AM
May-29-24 08:00AM
May-28-24 08:00AM
May-22-24 08:00AM
May-21-24 08:00AM
May-20-24 10:53AM
May-15-24 08:00AM
May-13-24 04:30PM
Apr-29-24 09:00AM
Apr-24-24 08:00AM
Apr-09-24 06:31AM
Apr-01-24 04:15PM
Mar-28-24 09:32AM
Mar-25-24 08:00AM
Mar-24-24 04:05PM
Mar-21-24 08:00AM
Mar-20-24 08:00AM
Mar-19-24 08:00AM
Mar-12-24 08:00AM
Mar-11-24 08:00AM
Mar-07-24 09:37AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Feb-29-24 08:00AM
Feb-28-24 08:00AM
Feb-27-24 08:00AM
Feb-26-24 08:00AM
Feb-25-24 02:12PM
Feb-23-24 09:30AM
Feb-20-24 08:00AM
Feb-16-24 09:30AM
Feb-15-24 08:45AM
Feb-14-24 08:00AM
Feb-13-24 08:00AM
Feb-12-24 08:00AM
Feb-01-24 08:00AM
Jan-31-24 07:00AM
Jan-30-24 05:00PM
Jan-29-24 07:00AM
Jan-26-24 05:31PM
Jan-25-24 07:00AM
Jan-24-24 03:28PM
Jan-09-24 07:00AM
Jan-03-24 07:00AM
Jan-02-24 06:08AM
Dec-20-23 10:35AM
Dec-14-23 09:15AM
Dec-12-23 01:40PM
Dec-11-23 07:00AM
Dec-04-23 07:00AM
Nov-28-23 07:00AM
Nov-20-23 01:57PM
Nov-15-23 07:00AM
Nov-13-23 07:00AM
Nov-09-23 04:15PM
Nov-02-23 08:00AM
Oct-31-23 05:00PM
Oct-30-23 07:00AM
Oct-26-23 07:00AM
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.